ArticleCancer research communications2024

A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer.

Matthew T Campbell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.